Casodex reduces prostate mortality

New data was presented today at the 13th European Cancer Conference (ECCO) confirming that treatment with ‘Casodex’ (bicalutamide) 150mg and radiotherapy reduces the risk of death in men with locally advanced prostate cancer by 35% compared treatment with radiotherapy alone.

Data was collected from the 3rd analysis of the EPC Trial Programme, the largest clinical trial carried out in the treatment of men with early prostate cancer. Results also demonstrated that ‘Casodex’ 150mg significantly delays disease progression in men with locally advanced prostate cancer irrespective of primary therapy – meeting a primary endpoint of the Trial.’Casodex’ 150mg is the only anti-androgen shown to have these results.